Item 7.01 Regulation FD Disclosure.
On January 9, 2023, Provectus Biopharmaceuticals, Inc. (the "Company") issued a
letter to stockholders providing an update on the Company's activities. A copy
of the letter to stockholders is attached to this Current Report on Form 8-K as
Exhibit 99.1 and is incorporated herein by reference.
Pursuant to the rules and regulations of the Securities and Exchange Commission,
the information in this Item 7.01 disclosure, including Exhibit 99.1 and
information set forth therein, is deemed to have been furnished and shall not be
deemed to be "filed" under the Securities Exchange Act of 1934, as amended.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1 Letter to Stockholders, dated January 9, 2023.
104 Cover Page Interactive Date File (the cover page XBRL tags are
embedded within the inline XBRL document).
© Edgar Online, source Glimpses